



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

14th February, 2024

Corporate Relationship Department
M/s. BSE Ltd.
Dalal Street,
Fort Mumbai – 400 001.
Scrip Code: 524816

The Manager – Listing
M/s. National Stock Exchange of India Ltd.
Exchange Plaza, Bandra-Kurla Complex
Bandra(E), Mumbai – 400 051.
Scrip Code: NATCOPHARM

Dear Sir/Madam,

Sub: Outcome of Board Meeting

Ref: Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015

Pursuant to Regulation 30 read with Schedule III Part A of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform that among other items of business the Board of Directors based on the recommendation of Nomination and Remuneration Committee, at its meeting held on 14th February, 2024 has, inter alia:

1. Approved the appointment of Sri Agnihotra Dakshina Murty Chavali (DIN:00374673) as Independent Director of the Company for a period of five (5) years w.e.f 1st April, 2024.
2. Approved the appointment of Sri Dronadula Vijaya Bhaskar (DIN: 07158951) as Independent Director of the Company for a period of five (5) years w.e.f. 1st April, 2024.
3. Approved the appointment of Sri Venkaiah Chowdary Nannapaneni (DIN: 00183315) as Chairman & Managing Director of the Company for a period of two (2) years w.e.f. 1st April, 2024 and payment of remuneration.
4. Approved the appointment of Sri Rajeev Nannapaneni (DIN: 00183872) as Vice Chairman & Chief Executive Officer of the Company for a period of two (2) years w.e.f. 1st April, 2024 and payment of remuneration.
5. Approved the re-appointment of Sri Potluri Sivaramakrishna Prasad (DIN: 07011140) as Director and Executive Vice President (Corporate Engineering Services) of the Company for a period of two (2) years w.e.f. 1st April, 2024 and payment of remuneration.
6. Approved the re-appointment of Dr. Donthineni Linga Rao (DIN: 07088404) as Director & President (Tech. Affairs) of the Company for a period of two (2) years w.e.f. 1st April, 2024 and payment of remuneration.



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

7. Approved the re-appointment of Dr. Pavan Ganapati Bhat (DIN: 09691260) as Director & Executive Vice President (Technical Operations) of the Company for a period of two (2) years w.e.f. 1st April, 2024 and payment of remuneration.

The Board also took note of Sri Gubbala Sreerama Murthy (DIN: 00122454) and Sri. Dasu Govinda Prasad (DIN: 00160408), Independent Directors of the Company, completing their second term of 5 years with effect from 1st April, 2024.

This is for your information and records.

Thanking you,

Your faithfully,
For Natco Pharma Limited

Ch. Venkat Ramesh
Company Secretary &
Compliance Officer

Encl: as above As Annexure



The details as required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, is as under:

Sl. No.	Particulars	(1) Sri Agnihotra Dakshina Murty Chavali	(2) Sri Dronadula Vijaya Bhaskar	(3) Sri Venkaiah Chowdary Nannapaneni
1.	Reason for change	Appointment as Independent Director of the Company	Appointment as Independent Director of the Company	Appointment as Chairman & Managing Director of the Company
2.	Date of appointment/re-appointment/cessation (as applicable) & term of appointment/re-appointment	With effect from 1 st April, 2024, for a period of five years, subject to approval of the shareholders of the Company.	With effect from 1 st April, 2024, for a period of five years, subject to approval of the shareholders of the Company.	With effect from 1 st April, 2024, for a period of two years, subject to approval of the shareholders of the Company.
3.	Brief profile (in case of appointment)	Sri A.D.M. Chavali has over three decades of experience in corporate finance concentrating in the areas of Industrial Finance, Treasury operations, Investments, Asset Management, Risk Management, etc. He worked as General Manager in Bank of Baroda, where he headed the treasury and resources management function of the Bank and enabled the evolution of Bank of Baroda treasury into a model treasury for other banks to imitate and emulate. In the year 2011, he joined the Indian Overseas Bank as an Executive Director. During his time in Indian Overseas Bank, he has a vast experience in portfolios covering Large Corporate Credit, International Business, Treasury Operations, Human Resources, Law/Recovery, Risk Management, Retail Banking, Planning,	Sri D. Vijaya Bhaskar has over three decades as an advocate in areas of Corporate Law, Corporate Governance, Joint Ventures, Due Diligence, Intellectual Property, Legal Advice and Drafting, Mergers & Acquisitions, Private Equity, Corporate Litigations, Economic Offences, etc. Currently, he is practicing as Advocate & Corporate Legal Consultant on Corporate Affairs and Strategic Litigations, providing back-end support to Senior Counsel in the cases arising out of investigations of CBI and Enforcement Directorate relating to Economic offences under PMLA, IPC and Commercial Laws and rendering legal advices on complicated corporate matters.	Sri V.C. Nannapaneni is associated with the Company as founder/promoter/mentor from incorporation of your Company. He has rich and varied experience in the industry and is driving the Company towards higher growth in terms of revenues as well as profitability. He is highly qualified. Sri V.C. Nannapaneni attained the age of 78 years (DOB: November 30, 1945) as on November 30, 2023. Services of Sri V.C. Nannapaneni are very much essential for the Company's future prospects and further growth of the Company. He is taking care of new product developments and their launch, overall guidance in clinical trials and R&D. It would be in the interest of the Company to have his vast experience and professional services as



Annexure

		Public Relations, Credit monitoring, etc. He also represented the Indian Banking industry as a delegate to the Indo-Russian sub-committee on Banking and Financial service led by RBI in Moscow in July 2014.		Chairman & Managing Director to your Company. The Board believes that the Company will benefit from his professional expertise and rich varied experience.
4.	Disclosure of relationships between directors (in case of appointment of a director)	He is not related to any of the Director.	He is not related to any of the Director.	Except Sri V.C. Nannapaneni & Sri Rajeev Nannapaneni, no other Director is related.
5.	Information as required pursuant to BSE Circular no. LIST/COMP/14/2018-19 & NSE circular no. NSE/CML/2018/24, dated June 20, 2018	He is not debarred from holding the office of Director pursuant to any SEBI Order or Order of any such Authority.	He is not debarred from holding the office of Director pursuant to any SEBI Order or Order of any such Authority.	He is not debarred from holding the office of Director pursuant to any SEBI Order or Order of any such Authority.



Annexure

Sl. No.	Particulars	(4) Sri Rajeev Nannapaneni	(5) Sri Potluri Sivaramakrishna Prasad	(6) Dr. Donthineni Linga Rao
1.	Reason for change	Appointment as Vice Chairman & Chief Executive Officer of the Company	Appointment as Director and Executive Vice President (Corporate Engineering Services) of the Company	Appointment as Director & President (Tech. Affairs) of the Company
2.	Date of appointment/re-appointment/cessation (as applicable) & term of appointment/re-appointment	With effect from 1 st April, 2024, for a period of two years, subject to approval of the shareholders of the Company.	With effect from 1 st April, 2024, for a period of two years, subject to approval of the shareholders of the Company.	With effect from 1 st April, 2024, for a period of two years, subject to approval of the shareholders of the Company.
3.	Brief profile (in case of appointment)	Sri Rajeev Nannapaneni, Vice Chairman & Chief Executive Officer is associated with the Company for the past 24 years and he is looking after all the functional operations of the Company including but not limited to Production, Financial, Legal & Secretarial, New Drug Launches, Domestic and International Marketing, Exports, Imports, etc.	Sri P.S.R.K. Prasad has over 34 years of experience in various sectors such as textile, chemicals and pharmaceuticals and working with our Company for the past 29 years. He has got vast and good knowledge in procuring right equipment(s) and machinery for production processes and to provide all utility services and to see that the resources like manpower, material to be used in an optimum way and to ensure safety of life and property.	Dr. D. Linga Rao is working as Director and President (Technical Affairs) of the Company. He has over 43 years of experience in the pharmaceutical industry and has been working with our Company for over 30 years. He is in-charge of various departments like R&D, Quality Control, Quality Assurance and Regulatory affairs of Chemical Division(s).
4.	Disclosure of relationships between directors (in case of appointment of a director)	Except Sri V.C. Nannapaneni & Sri Rajeev Nannapaneni, no other Director is related.	He is not related to any of the Director.	He is not related to any of the Director.
5.	Information as required pursuant to BSE Circular no. LIST/COMP/14/2018-19 & NSE circular no. NSE/CML/2018/24, dated June 20, 2018	He is not debarred from holding the office of Director pursuant to any SEBI Order or Order of any such Authority.	He is not debarred from holding the office of Director pursuant to any SEBI Order or Order of any such Authority.	He is not debarred from holding the office of Director pursuant to any SEBI Order or Order of any such Authority.



Annexure

Sl. No.	Particulars	(7) Dr. Pavan Ganapati Bhat	(8) Sri Gubbala Sreerama Murthy	(9) Sri. Dasu Govinda Prasad
1.	Reason for change	Appointment as Director & Executive Vice President (Technical Operations) of the Company	Completion of second term of five years	Completion of second term of five years
2.	Date of appointment/re-appointment/cessation (as applicable) & term of appointment/re-appointment	With effect from 1 st April, 2024, for a period of two years, subject to approval of the shareholders of the Company.	With effect from 1 st April, 2024	With effect from 1 st April, 2024
3.	Brief profile (in case of appointment)	<p>Dr. Pavan Ganapati Bhat (Dr. Pavan Bhat) is working as Director & Executive Vice President (Technical Operations) of the Company. He has over 25+ years of experience in the Pharmaceutical Industry and has been working with our Company for past 6 years. He is in-charge of various departments like R&D, Regulatory Affairs for Generics, NDDS and NCEs, Intellectual Property Rights of Formulations and Acquisitions.</p> <p>Dr. Pavan Bhat started his career with Mylan in USA in Transdermal R&D followed by OSD R&D and in Corporate & Business Development. As part of the Office of the CEO, he was a key member of the acquisition team of Matrix by Mylan followed by being a part of the Integration team. He then relocated to Mylan India where he Headed Mylan's Global External R&D and Regional Business Development. Finally, he was the Head of Regional Operations responsible for Portfolio Selection, Project Management, Supply Chain Management, Launch Management, Logistics and Special Projects and supporting a P&L of \$ 1.2 Billion.</p>	Not Applicable	Not Applicable
4.	Disclosure of relationships between directors (in case of appointment of a director)	He is not related to any of the Director.	Not Applicable	Not Applicable
5.	Information as required pursuant to BSE Circular no. LIST/COMP/14/2018-19 & NSE circular no. NSE/CML/2018/24, dated June 20, 2018	He is not debarred from holding the office of Director pursuant to any SEBI Order or Order of any such Authority.	Not Applicable	Not Applicable